DUBLIN, March 4,
2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty
pharmaceutical company, today announced that Paul O'Neill has been appointed Executive Vice
President, Quality & Operations, Specialty Brands, effective
immediately. Mr. O'Neill previously served as the Company's Senior
Vice President, Quality & Operations, Specialty Brands. He will
continue to be responsible for leading Quality & Operations for
Mallinckrodt's Specialty Brands
business, overseeing internal and external manufacturing, supply
chain distribution, device engineering, quality, technical services
and product support. In addition, Mr. O'Neill will join the
Company's Executive Committee.
Since joining Mallinckrodt, Mr.
O'Neill has led several key initiatives in Mallinckrodt's Specialty Brands business. He has
more than 25 years of experience in manufacturing operations, plant
start-ups, technology transfer and supply chain management and has
held numerous leadership positions at biopharmaceutical companies,
including Merck, Pfizer and Wyeth. Prior to joining Mallinckrodt in March
2023, Mr. O'Neill served as Executive Director, Biologics
Operations, at Merck where he was responsible for the supply
strategy of Keytruda.
"Paul has been instrumental in driving transformational change
to stabilize the Specialty Brands portfolio supply performance,
establishing a high-performance culture within the Quality &
Operations organization, as well as preparing for the launches of
our INOmax® EVOLVE™ DS Delivery System and
Acthar® Gel (repository corticotropin injection)
Single-Dose Pre-filled SelfJect™," said Siggi Olafsson, President and Chief Executive
Officer. "We are pleased that he will be taking on a broader
leadership role as a member of our Executive Committee. I look
forward to continuing to work alongside him as we advance our
efforts to ensure patients' access to our therapies."
Mr. O'Neill said, "I am honored to take on this role and
collaborate with the other members of the Executive Committee.
Together we will build on the important progress our leadership
team has made across the business to date to position Mallinckrodt for long-term growth."
About Paul O'Neill
Mr. O'Neill joined Mallinckrodt as
Senior Vice President, Quality & Operations, Specialty Brands,
in March 2023. Before joining
Mallinckrodt, he served as Executive
Director, Biologics Operations, at Merck, and was responsible for
overseeing the end-to-end supply strategy of Merck's Keytruda and
biologics (mABs) pipeline portfolio. Prior to that, Mr. O'Neill
held leadership positions at Pfizer and Wyeth in plant operations,
supply chain management, new product launches, site start-ups and
network design.
Mr. O'Neill holds an MBA from the Alfred Lerner College of
Business & Economics at the University of
Delaware and a BSc in Food Science and Technology from
University College of Cork.
About Mallinckrodt
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The Company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, hepatology,
nephrology, pulmonology, ophthalmology and oncology; immunotherapy
and neonatal respiratory critical care therapies; analgesics; and
gastrointestinal products. Its Specialty Generics reportable
segment includes specialty generic drugs and active pharmaceutical
ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission ("SEC") disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
Investor
Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag /
Aaron Palash / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2024.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-announces-appointment-of-paul-oneill-as-executive-vice-president-quality--operations-specialty-brands-302077908.html
SOURCE Mallinckrodt plc